Also from this source


You just read:

Escend Pharmaceuticals, Inc. Receives Orphan Drug Designation from the US Food and Drug Administration (FDA) for ES-3000 its Lead Compound in the Treatment of Chronic Myeloid Leukemia (CML)

News provided by

Escend Pharmaceuticals, Inc.

02 Jun, 2016, 16:00 ET